Omeros: YARTEMLEA Is Off To A Blistering Start (NASDAQ:OMER)
· seekingalpha.com
Omeros (OMER) Buy thesis: YARTEMLEA launch beats expectations ($28.5M sales, positive cash flow), faster adoption and lower dilution risk—read now.
When it comes to Omeros Corporation ( OMER ), I would be buy-rated here since the 2Q26 call showed us that YARTEMLEA is ramping significantly faster than expect...